|This article needs additional citations for verification. (March 2015) (Learn how and when to remove this template message)|
|Systematic (IUPAC) name|
|Trade names||Usevir, Brovavir|
|Metabolism||Viral thymidine kinase|
|Synonyms||BV-araU, Bromovinyl araU, 5-Bromovinyl-araU, 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione|
|Molar mass||349.14 g/mol|
|(what is this?)|
- First-line treatment of herpes drug acyclovir was (Zovirax, Activir) from VZV strong activity of the virus.
- Superior[weasel words] gastrointestinal absorption, absorption from the gastrointestinal tract after the most degrading without being excreted as urine.
Mechanism of action
- Sorivudine is phosphorylated by thymidine kinase activity in the body and is absorbed into the virus's DNA instead of the correct nucleoside. It is a competitive inhibitor of DNA polymerase, so the viral DNA cannot be replicated and the virus cannot grow.
Sorivudine is active against most species in the herpesvirus family.
Sorivudine interacts strongly and in some cases lethally with fluorouracil (5-FU), its prodrugs and related substances. This is based on the metabolite bromovinyluracil (BVU), which irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. The closely related drug brivudine has the same interaction.
- "UAW – Aus Fehlern lernen - Potenziell tödlich verlaufende Wechselwirkung zwischen Brivudin (Zostex) und 5-Fluoropyrimidinen" (PDF). Deutsches Ärzteblatt (in German). 103 (27). 7 July 2006.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|